StoryResearch
AgelessRx names itself a semifinalist in $101M XPRIZE Healthspan competition
AgelessRx announced its selection as a semifinalist in the XPRIZE Healthspan competition, a $101M global race to extend healthspan. The company's PEARL trial, testing rapamycin in healthy aging, became the basis for its competition entry.